A Critical Review on Nanoscience Advancement: In Treatment of Viral Infection

  • Kajal Chaudhary Assistant Professor, Department of Pharmacy, Metro College of Health Sciences and Research, Greater Noida, Uttar Pradesh-201310, India
  • Shweta Parihar Research Scholar, Department of Pharmacognosy, Maharshi Dayanand University, Near Delhi Bypass, Rohtak, Haryana-124001, India
  • Devender Sharma Research Scholar, Department of Pharmaceutics, Lovely Institute of Technology (Pharmacy), Lovely Professional University, Punjab-144411, India

Abstract

Viral contaminations speak to a general medical issue and one of the main sources of worldwide mortality. A large portion of the antiviral medications have low permeability, low dissolvability and other related physical properties which make them less efficient for the antiviral treatment. To conquer these constraints, different nanomedicine stages have been planned. Nanomaterials offer special physico-chemical properties that have various advantages for medicate conveyance as perfect devices for viral treatment. This review focuses on the currently used medicines used in viral infection, presents a broad overview of the application of nanosized materials for the treatment of common viral infections and shed light on the potential of nanotechnology to provide more effective treatment for HIV, Herpes simplex virus, Influenza virus and Hepatitis C virus. The action of antiviral medications could be improved with nanomedicine formulations. As the physicochemical properties of nanocarriers can empower their capacity to target the specific sites. When it comes to structuring nanocarriers, size is the most important factor and the nanoparticles can permit the controlled delivery kinetics, enhanced bioavailability, altered pharmacokinetics, and less side effects. Nanocarriers that build them appealing candidates for antiviral drug such as Improves bioavailability of the encapsulated actives, controlled release, reduce the toxicity associated with the anti-viral drugs. One of the important physicochemical properties mainly size is the most important design factor for nanocarriers for anti-viral drug delivery to the specific sites. Nanobased drug delivery also leads to enhance the potential of currently approved antiviral drugs.


Keywords: Nanotechnology, HIV, Hepatits virus, Influenza, HSV

Keywords: Nanotechnology, HIV, Hepatits virus, Influenza, HSV

Downloads

Download data is not yet available.

Author Biographies

Kajal Chaudhary, Assistant Professor, Department of Pharmacy, Metro College of Health Sciences and Research, Greater Noida, Uttar Pradesh-201310, India

Assistant Professor, Department of Pharmacy, Metro College of Health Sciences and Research, Greater Noida, Uttar Pradesh-201310, India

Shweta Parihar, Research Scholar, Department of Pharmacognosy, Maharshi Dayanand University, Near Delhi Bypass, Rohtak, Haryana-124001, India

Research Scholar, Department of Pharmacognosy, Maharshi Dayanand University, Near Delhi Bypass, Rohtak, Haryana-124001, India

Devender Sharma, Research Scholar, Department of Pharmaceutics, Lovely Institute of Technology (Pharmacy), Lovely Professional University, Punjab-144411, India

Associate Professor, Department of Pharmaceutics, R. J. World College of Pharmacy Education and Technology,  Jakhod, Surajgarh, Rajasthan -333033, India

References

1. Akbarzadeh A, Kafshdooz L, Razban Z, DastranjTbrizi A, Rasoulpour S, Khalilov R, Kavetskyy T, Saghfi S, Nasibova AN, Kaamyabi S, Kafshdooz T. An overview application of silver nanoparticles in inhibition of herpes simplex virus. Artif Cells NanomedBiotechnol. 2018; 46(2):263-267. doi: 10.1080/21691401.2017.1307208. Epub 2017 Apr 12. PMID: 28403676.
2. Singh L, Kruger HG, Maguire GEM, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis. 2017; 4(4):105-131. doi:10.1177/2049936117713593
3. Milroy D, Featherstone J. Antiviral market overview. Nat Rev Drug Discov. 2002 Jan; 1(1):11-2. doi: 10.1038/nrd709. PMID: 12119604.
4. Lembo D, Cavalli R. Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother. 2010; 21(2):53-70. doi: 10.3851/IMP1684. PMID: 21107015.
5. Szunerits S, Barras A, Khanal M, Pagneux Q, Boukherroub R. Nanostructures for the Inhibition of Viral Infections. Molecules. 2015 Aug 3; 20(8):14051-81. doi: 10.3390/molecules200814051. PMID: 26247927; PMCID: PMC6332336.
6. Szunerits S, Barras A, Khanal M, Pagneux Q, Boukherroub R. Nanostructures for the Inhibition of Viral Infections. Molecules. 2015 Aug 3; 20(8):14051-81. doi: 10.3390/molecules200814051. PMID: 26247927; PMCID: PMC6332336.
7. Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv. 2018 Jan; 15(1):93-114. doi: 10.1080/17425247.2017.1360863. Epub 2017 Aug 3. PMID: 28749739.
8. Van Regenmortel M.H.V. Genetics and Evolution of Infectious Disease. Elsevier; Amsterdam, The Netherlands: 2011. Virus Species, 3–19.
9. Heikkinen T, Järvinen A. The common cold. Lancet. 2003 Jan 4; 361(9351):51-9. doi: 10.1016/S0140-6736(03)12162-9. PMID: 12517470; PMCID: PMC7112468.
10. Watson S, Cabrera-Aguas M, Khoo P. Common eye infections. AustPrescr. 2018 Jun; 41(3):67-72. doi: 10.18773/austprescr.2018.016. Epub 2018 Jun 1. PMID: 29922000; PMCID: PMC6003010.
11. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011 Apr 9; 377(9773):1264-75. doi: 10.1016/S0140-6736(10)61459-6. Epub 2011 Mar 22. PMID: 21435708; PMCID: PMC7138033.
12. Thuener J. Hepatitis A and B Infections. Prim Care. 2017 Dec; 44(4):621-629. doi: 10.1016/j.pop.2017.07.005. Epub 2017 Oct 5. PMID: 29132524.
13. Ahmad J. Hepatitis C. BMJ. 2017 Jul 6; 358:j2861. doi: 10.1136/bmj.j2861. PMID: 28684552.
14. Rizzetto M. Hepatitis D Virus: Introduction and Epidemiology. Cold Spring HarbPerspect Med. 2015 Jul 1; 5(7):a021576. doi: 10.1101/cshperspect.a021576. PMID: 26134842; PMCID: PMC4484953.
15. Khuroo MS, Khuroo MS, Khuroo NS. Hepatitis E: Discovery, global impact, control and cure. World J Gastroenterol. 2016 Aug 21; 22(31):7030-45. doi: 10.3748/wjg.v22.i31.7030. PMID: 27610014; PMCID: PMC4988308.
16. Cojocaru FD, Botezat D, Gardikiotis I, Uritu CM, Dodi G, Trandafir L, Rezus C, Rezus E, Tamba BI, Mihai CT. Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers. Pharmaceutics. 2020 Feb 18; 12(2):171. doi: 10.3390/pharmaceutics12020171. PMID: 32085535; PMCID: PMC7076512.
17. Hékimian G, Combes A. Myocardites [Myocarditis]. Rev Med Interne. 2017 Aug; 38(8):531-538. French. doi: 10.1016/j.revmed.2016.12.022. Epub 2017 Feb 2. PMID: 28161113.
18. Rawla P, Sathyajit S. Bandaru ,Vellipuram AR.Review of infectious etiology of acute pancreatitis .Gastroenterol Res,2017 Jun 30; 10(3):153-158.
19. Eckardt AJ, Baumgart DC. Viral gastroenteritis in adults. Recent Pat Antiinfect Drug Discov. 2011 Jan; 6(1):54-63. doi: 10.2174/157489111794407877. PMID: 21210762.
20. Gilson RJ, Mindel A. Recent advances: Sexually transmitted infections. BMJ. 2001 May 12; 322(7295):1160-4. doi: 10.1136/bmj.322.7295.1160. PMID: 11348912; PMCID: PMC1120285.
21. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009 May; 49(5 Suppl):S13-21. doi: 10.1002/hep.22881. PMID: 19399811; PMCID: PMC2809016.
22. Wu CC, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. World J Gastroenterol. 2018 Aug 21; 24(31):3488-3499. doi: 10.3748/wjg.v24.i31.3488. PMID: 30131655; PMCID: PMC6102499.
23. Keeffe EB, Marcellin P. New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol. 2007 Mar;5(3):285-94. doi: 10.1016/j.cgh.2006.09.036. Epub 2007 Jan 9. PMID: 17218162.
24. Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases. 2019 Jul 26; 7(14):1784-1794. doi: 10.12998/wjcc.v7.i14.1784. PMID: 31417924; PMCID: PMC6692272.
25. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol. 2008; 3:499-522. doi: 10.1146/annurev.pathmechdis.3.121806.154316. PMID: 18039138; PMCID: PMC2504709.
26. ArbeitskreisBlut, Untergruppe «BewertungBlutassoziierterKrankheitserreger». Influenza Virus. Transfus Med Hemother. 2009;36(1):32-39. doi: 10.1159/000197314. PMID: 21048819; PMCID: PMC2928832.
27. Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv. 2018 Jan; 15(1):93-114. doi: 10.1080/17425247.2017.1360863. Epub 2017 Aug 3. PMID: 28749739.
28. Cao Q, Wu H, Zhu L, Wu D, Zhu Y, Zhu Z, Cui J. Preparation and evaluation of zanamivir-loaded solid lipid nanoparticles. J Control Release. 2011 Nov 30; 152 Suppl1:e2-4. doi: 10.1016/j.jconrel.2011.08.085. PMID: 22195851.
29. Crimi S, Fiorillo L, Bianchi A, D'Amico C, Amoroso G, Gorassini F, Mastroieni R, Marino S, Scoglio C, Catalano F, Campagna P, Bocchieri S, De Stefano R, Fiorillo MT, Cicciù M. Herpes Virus, Oral Clinical Signs and QoL: Systematic Review of Recent Data. Viruses. 2019 May 21; 11(5):463. doi: 10.3390/v11050463. PMID: 31117264; PMCID: PMC6563194.
30. Perret F, Duffour M, Chevalier Y, Parrot-Lopez H. Design, synthesis, and in vitro evaluation of new amphiphilic cyclodextrin-based nanoparticles for the incorporation and controlled release of acyclovir. Eur J Pharm Biopharm. 2013 Jan; 83(1):25-32. doi: 10.1016/j.ejpb.2012.09.013. Epub 2012 Oct 13. PMID: 23072941.
31. Lembo D, Swaminathan S, Donalisio M, Civra A, Pastero L, Aquilano D, Vavia P, Trotta F, Cavalli R. Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent's antiviral efficacy. Int J Pharm. 2013 Feb 25; 443(1-2):262-72. doi: 10.1016/j.ijpharm.2012.12.031. Epub 2012 Dec 30. PMID: 23279938.
32. Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol. 2018 Feb 27;1 0(2):186-212. doi: 10.4254/wjh.v10.i2.186. PMID: 29527256; PMCID: PMC5838439.
33. Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002 Nov; 36(5 Suppl 1):S93-8. doi: 10.1053/jhep.2002.36389. PMID: 12407581.
34. Lai L, Hui CK, Leung N, Lau GK. Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B. Int J Nanomedicine. 2006; 1(3):255-62. PMID: 17717966; PMCID: PMC2426802.
35. De Clercq E, Férir G, Kaptein S, Neyts J. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses. 2010 Jun; 2(6):1279-305. doi: 10.3390/v2061279. Epub 2010 May 31. PMID: 21994680; PMCID: PMC3185710.
36. De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul; 29(3):695-747. doi: 10.1128/CMR.00102-15. PMID: 27281742; PMCID: PMC4978613.
37. McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses. 2013 Jan; 7 Suppl 1(Suppl 1):25-36. doi: 10.1111/irv.12047. PMID: 23279894; PMCID: PMC4942987.
38. Modi S, Van L, Gewirtzman A, Mendoza N, Bartlett B, Tremaine AM, Tyring S. Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology. Ther Clin Risk Manag. 2008 Apr; 4(2):409-17. doi: 10.2147/tcrm.s1664. PMID: 18728852; PMCID: PMC2504076.
39. De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul; 29(3):695-747. doi: 10.1128/CMR.00102-15. PMID: 27281742; PMCID: PMC4978613.
40. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring HarbPerspect Med. 2011 Sep; 1(1):a006841. doi: 10.1101/cshperspect.a006841. PMID: 22229120; PMCID: PMC3234451.
41. Arts Eric J,Daria HJ.Hiv -1 Antiretroviral drug therapy . Cold Spring HarbPerspect Med. 2012; 2(4):a007161.
42. McGowan I. An overview of antiretroviral pre-exposure prophylaxis of HIV infection. Am J Reprod Immunol. 2014 Jun; 71(6):624-30. doi: 10.1111/aji.12225. Epub 2014 Mar 17. PMID: 24635047.
43. Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. 2013 Sep 4; 16(1):1-14. doi: 10.7448/IAS.16.1.18567. PMID: 24008177; PMCID: PMC3764307.
44. Liao C, Marchand C, Burke TR Jr, Pommier Y, Nicklaus MC. Authentic HIV-1 integrase inhibitors. Future Med Chem. 2010 Jul; 2(7):1107-22. doi: 10.4155/fmc.10.199. PMID: 21426159; PMCID: PMC3413320.
45. Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl). 2015 Apr 8; 7:95-104. doi: 10.2147/HIV.S79956. PMID: 25897264; PMCID: PMC4396582.
46. Qian K, Morris-Natschke SL, Lee KH. HIV entry inhibitors and their potential in HIV therapy. Med Res Rev. 2009 Mar; 29(2):369-93. doi: 10.1002/med.20138. PMID: 18720513; PMCID: PMC3773846.
47. De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul; 29(3):695-747. doi: 10.1128/CMR.00102-15. PMID: 27281742; PMCID: PMC4978613.
48. Singh L, Kruger HG, Maguire GEM, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis. 2017 Jul; 4(4):105-131. doi: 10.1177/2049936117713593. Epub 2017 Jul 5. PMID: 28748089; PMCID: PMC5507392.
49. Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M; NanoImpactNet Consortium. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond). 2013 Mar; 8(3):449-67. doi: 10.2217/nnm.13.8. PMID: 23477336.
50. Mehendale R, Joshi M, Patravale VB. Nanomedicines for treatment of viral diseases. Crit Rev Ther Drug Carrier Syst. 2013; 30(1):1-49. doi: 10.1615/critrevtherdrugcarriersyst.2013005469. PMID: 23510109.
51. Parboosing R, Maguire GE, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. Viruses. 2012 Apr; 4(4):488-520. doi: 10.3390/v4040488. Epub 2012 Apr 10. PMID: 22590683; PMCID: PMC3347320.
52. Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev. 2010 Mar 18; 62(4-5):503-17. doi: 10.1016/j.addr.2009.11.020. Epub 2009 Nov 13. PMID: 19914319.
53. Lembo D, Cavalli R. Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother. 2010; 21(2):53-70. doi: 10.3851/IMP1684. PMID: 21107015.
54. Mehendale R, Joshi M, Patravale VB. Nanomedicines for treatment of viral diseases. Crit Rev Ther Drug Carrier Syst. 2013; 30(1):1-49. doi: 10.1615/critrevtherdrugcarriersyst.2013005469. PMID: 23510109.
55. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology. 2011 Nov 28; 9:55. doi: 10.1186/1477-3155-9-55. PMID: 22123084; PMCID: PMC3238292.
56. Chattopadhyay N, Zastre J, Wong HL, Wu XY, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res. 2008 Oct; 25(10):2262-71. doi: 10.1007/s11095-008-9615-2. Epub 2008 May 31. PMID: 18516666.
57. GongP, LiH, He X, Wang K, Hu J, Tan W, ZhangS, YangX. Preparation and antibacterial activity of Fe304 Ag NP. Nanotechnology. 2007 Nov 28. 18:285-604.
58. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology. 2005 Jun 29; 3:6. doi: 10.1186/1477-3155-3-6. PMID: 15987516; PMCID: PMC1190212.
59. Cui Y, Zhao Y, Tian Y, Zhang W, Lü X, Jiang X. The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli. Biomaterials. 2012 Mar; 33(7):2327-33. doi: 10.1016/j.biomaterials.2011.11.057. Epub 2011 Dec 17. PMID: 22182745.
60. Rafiei S, Rezatofighi SE, RoayaeiArdakani M, Rastegarzadeh S. Gold Nanoparticles Impair Foot-and-Mouth Disease Virus Replication. IEEE Trans Nanobioscience. 2016 Jan; 15(1):34-40. doi: 10.1109/TNB.2015.2508718. Epub 2015 Dec 17. PMID: 26685261.
61. Ahmed SR, Kim J, Suzuki T, Lee J, Park EY. Detection of influenza virus using peroxidase-mimic of gold nanoparticles. BiotechnolBioeng. 2016 Oct; 113(10):2298-303. doi: 10.1002/bit.25982. Epub 2016 Aug 9. PMID: 27002303.
62. Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: Principles, Properties, and Regulatory Issues. Front Chem. 2018 Aug 20; 6:360. doi: 10.3389/fchem.2018.00360. PMID: 30177965; PMCID: PMC6109690.
63. Tyssen D, Henderson SA, Johnson A, Sterjovski J, Moore K, La J, Zanin M, Sonza S, Karellas P, Giannis MP, Krippner G, Wesselingh S, McCarthy T, Gorry PR, Ramsland PA, Cone R, Paull JR, Lewis GR, Tachedjian G. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One. 2010 Aug 23; 5(8):e12309. doi: 10.1371/journal.pone.0012309. PMID: 20808791; PMCID: PMC2925893.
64. Pradhan D, Biswasroy P, Goyal A, Ghosh G, Rath G. Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections. AAPS PharmSciTech. 2021 Jan 14; 22(1):47. doi: 10.1208/s12249-020-01908-5. PMID: 33447909; PMCID: PMC7808403.
65. Lembo D, Cavalli R. Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother. 2010; 21(2):53-70. doi: 10.3851/IMP1684. PMID: 21107015.
66. Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007 Mar; 65(3):259-69. doi: 10.1016/j.ejpb.2006.11.009. Epub 2006 Nov 23. PMID: 17196803.
67. Milovanovic M, Arsenijevic A, Milovanovic J, Kanjevac T, Arsenijevic N. Nanoparticles in Antiviral Therapy. Antimicrobial Nanoarchitectonics. 2017; 383–410. doi: 10.1016/B978-0-323-52733-0.00014-8. Epub 2017 Jun 30. PMCID: PMC7173505.
68. Moretton MA, Glisoni RJ, Chiappetta DA, Sosnik A. Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf B Biointerfaces. 2010 Sep 1; 79(2):467-79. doi: 10.1016/j.colsurfb.2010.05.016. PMID: 20627665.
69. Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2015 Apr; 5(2):123-127. doi: 10.1007/s13205-014-0214-0. Epub 2014 Apr 8. PMID: 28324579; PMCID: PMC4362737.
70. Furin JJ, Behforouz HL, Shin SS, Mukherjee JS, Bayona J, Farmer PE, Kim JY, Keshavjee S. Expanding global HIV treatment: case studies from the field. Ann N Y Acad Sci. 2008; 1136:12-20. doi: 10.1196/annals.1425.004. Epub 2007 Oct 22. PMID: 17954668.
71. Chiodo F, Marradi M, Calvo J, Yuste E, Penadés S. Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs. Beilstein J Org Chem. 2014 Jun 12; 10:1339-46. doi: 10.3762/bjoc.10.136. PMID: 24991287; PMCID: PMC4077455.
72. Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA. Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother. 2010 Oct; 65(10):2183-7. doi: 10.1093/jac/dkq318. Epub 2010 Aug 21. PMID: 20729545; PMCID: PMC2941676.
73. Jenita JL, Chocalingam V, Wilson B. Albumin nanoparticles coated with polysorbate 80 as a novel drug carrier for the delivery of antiretroviral drug-Efavirenz. Int J Pharm Investig. 2014 Jul; 4(3):142-8. doi: 10.4103/2230-973X.138348. PMID: 25126528; PMCID: PMC4131386.
74. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006 Oct 10; 115(2):216-25. doi: 10.1016/j.jconrel.2006.07.021. Epub 2006 Jul 25. PMID: 16959358.
75. Elberry MH, Darwish NHE, Mousa SA. Hepatitis C virus management: potential impact of nanotechnology. Virol J. 2017 May 2; 14(1):88. doi: 10.1186/s12985-017-0753-1. PMID: 28464951; PMCID: PMC5414367.
76. Liu G, Xu D, Jiang M, Yuan W. Preparation of bioactive interferon alpha-loaded polysaccharide nanoparticles using a new approach of temperature-induced water phase/water-phase emulsion. Int J Nanomedicine. 2012; 7:4841-8. doi: 10.2147/IJN.S35502. Epub 2012 Sep 7. Retraction in: Int J Nanomedicine. 2018 Apr 19; 13:2277. PMID: 22973103; PMCID: PMC3439862.
77. Jiménez-Pardo I, González-Pastor R, Lancelot A, Claveria-Gimeno R, Velázquez-Campoy A, Abian O, Ros MB, Sierra T. Shell Cross-Linked Polymeric Micelles as Camptothecin Nanocarriers for Anti-HCV Therapy. MacromolBiosci. 2015 Oct; 15(10):1381-91. doi: 10.1002/mabi.201500094. Epub 2015 Jun 5. PMID: 26045353.
78. Lee MY, Yang JA, Jung HS, Beack S, Choi JE, Hur W, Koo H, Kim K, Yoon SK, Hahn SK. Hyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infection. ACS Nano. 2012 Nov 27; 6(11):9522-31. doi: 10.1021/nn302538y. Epub 2012 Oct 26. PMID: 23092111.
79. Nanda A, Saravanan M. Biosynthesis of silver nanoparticles from Staphylococcus aureus and its antimicrobial activity against MRSA and MRSE. Nanomedicine. 2009 Dec; 5(4):452-6. doi: 10.1016/j.nano.2009.01.012. Epub 2009 Feb 13. PMID: 19523420.
80. Ishihara T, Kaneko K, Ishihara T, Mizushima T. Development of biodegradable nanoparticles for liver-specific ribavirin delivery. J Pharm Sci. 2014 Dec; 103(12):4005-4011. doi: 10.1002/jps.24219. Epub 2014 Oct 21. PMID: 25335768.
81. Abo-Zeid YM, Urbanowicz RA, Tarr AW, Irving WL, Thomson BJ, Garnett MC. Nanoparticles as a promising delivery system to improve hepatitis C treatment (2014). www.semanticscholar.org/paper/Nanoparticles-as-a-Promising-Delivery-System-to-C-Abo-zeid-Urbanowicz/653ba60c026716b8f040cefa70f86ceedfb037b4
82. Ryoo SR, Jang H, Kim KS, Lee B, Kim KB, Kim YK, Yeo WS, Lee Y, Kim DE, Min DH. Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown. Biomaterials. 2012 Mar; 33(9):2754-61. doi: 10.1016/j.biomaterials.2011.12.015. Epub 2011 Dec 27. PMID: 22206595.
83. Ge Q, Dallas A, Ilves H, Shorenstein J, Behlke MA, Johnston BH. Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA. 2010 Jan; 16(1):118-30. doi: 10.1261/rna.1901810. Epub 2009 Nov 30. PMID: 19948766; PMCID: PMC2802022.
84. Al-Dhubiab BE, Nair AB, Kumria R, Attimarad M, Harsha S. Formulation and evaluation of nano based drug delivery system for the buccal delivery of acyclovir. Colloids Surf B Biointerfaces. 2015 Dec 1; 136:878-84. doi: 10.1016/j.colsurfb.2015.10.045. Epub 2015 Oct 31. PMID: 26547315.
85. Baram-Pinto D, Shukla S, Perkas N, Gedanken A, Sarid R. Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate. Bioconjug Chem. 2009 Aug 19; 20(8):1497-502. doi: 10.1021/bc900215b. Epub 2009 Jul 8. PMID: 21141805.
86. Szymańska E, Orłowski P, Winnicka K, Tomaszewska E, Bąska P, Celichowski G, Grobelny J, Basa A, Krzyżowska M. Multifunctional Tannic Acid/Silver Nanoparticle-Based Mucoadhesive Hydrogel for Improved Local Treatment of HSV Infection: In Vitro and In Vivo Studies. Int J Mol Sci. 2018 Jan 28; 19(2):387. doi: 10.3390/ijms19020387. PMID: 29382085; PMCID: PMC5855609.
87. Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm. 2013 Apr; 39(4):508-19. doi: 10.3109/03639045.2012.665460. Epub 2012 Mar 19. PMID: 22424312.
88. Xiang DX, Chen Q, Pang L, Zheng CL. Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. J Virol Methods. 2011 Dec; 178(1-2):137-42. doi: 10.1016/j.jviromet.2011.09.003. Epub 2011 Sep 17. PMID: 21945220.
89. MazurkovaaNA, SpitsynaaYE, ShikinacN.V, IsmagilovcZR, Zagrebel’nyia SN,Ryabchikovaa EI.Interaction of titanium dioxide nanoparticle with influenza virus.Nanotechnology Russia. 2010; 5:417-420.
90. Tao W, Ziemer KS, Gill HS. Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. Nanomedicine (Lond). 2014 Feb; 9(2):237-51. doi: 10.2217/nnm.13.58. Epub 2013 Jul 5. PMID: 23829488; PMCID: PMC3958969.
91. Papp I, Sieben C, Ludwig K, Roskamp M, Böttcher C, Schlecht S, Herrmann A, Haag R. Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles. Small. 2010 Dec 20; 6(24):2900-6. doi: 10.1002/smll.201001349. PMID: 21104827.
92. Ghaffari H, Tavakoli A, Moradi A, Tabarraei A, Bokharaei-Salim F, Zahmatkeshan M, Farahmand M, Javanmard D, Kiani SJ, Esghaei M, Pirhajati-Mahabadi V, Monavari SH, Ataei-Pirkooh A. Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine. J Biomed Sci. 2019 Sep 10; 26(1):70. doi: 10.1186/s12929-019-0563-4. PMID: 31500628; PMCID: PMC6734352.
93. Sharma D, Ali AAE, Trivedi LR; An Updated Review on: Liposomes as drug delivery system; PharmaTutor; 2018; 6(2):50-62; http://dx.doi.org/10.29161/PT.v6.i2.2018.50
94. Sharma, D., & Kosankar, K. V. Green Tea in Green World an updated review. PharmaTutor, 2018; 6(3):9-16. https://doi.org/10.29161/PT.v6.i3.2018.9.
95. Shweta Parihar, Devender Sharma, "NAVAGRAHA(NINE PLANETS) PLANTS: THE TRADITIONAL USES AND THE THERAPEUTIC POTENTIAL OF NINE SACRED PLANTS OF INDIA THAT SYMBOLISES NINE PLANETS", International Journal of Research and Analytical Reviews (IJRAR), 2021; 8(4):96-108.
96. Sharma, D., & Bhujbale, A. A. Phytosomes is a Novel Drug Delivery System based herbal formulation: An Review. PharmaTutor, 2018; 6(3):23-26. https://doi.org/10.29161/PT.v6.i3.2018.23
97. Sharma, D. Microneedles: an approach in transdermal drug delivery: a Review. PharmaTutor, 2018; 6(1):7-15. https://doi.org/10.29161/PT.v6.i1.2018.7.
98. Sharma, D., Ali, A. A. E., & Aate, J. R. Niosomes as Novel Drug Delivery System: Review Article. PharmaTutor, 2018; 6(3):58-65. https://doi.org/10.29161/PT.v6.i3.2018.58
99. Chaudhary, K., & Sharma, D. Cubosomes: A Potential Drug Delivery System. Asian Journal of Pharmaceutical Research and Development, 2021; 9(5):93-101. https://doi.org/https://doi.org/10.22270/ajprd.v9i5.981.
100. Lanjewar, A., Maurya, S., Sharma, D., & Gaur, A. Review on Hair Problem and its Solution. Journal of Drug Delivery and Therapeutics, 2020; 10(3-s):322-329. https://doi.org/10.22270/jddt.v10i3-s.4066
Statistics
62 Views | 1 Downloads
How to Cite
1.
Chaudhary K, Parihar S, Sharma D. A Critical Review on Nanoscience Advancement: In Treatment of Viral Infection. JDDT [Internet]. 15Nov.2021 [cited 1Dec.2021];11(6):225-37. Available from: https://jddtonline.info/index.php/jddt/article/view/5030